Registration for a live webinar on 'Innovations in antibiotic discovery: combating resistant infections' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Cancer and Oncology
-
3. Latest advances in the development of CAR & TCR T-cell treatments for solid tumours
- Dr. Else Marit Inderberg
-
4. Mode of action of T cells engineered with CAR or TCR for cancer treatment
- Prof. Sebastian Kobold
-
5. Immunotherapy: insights from advanced disease
- Dr. Sara M. Tolaney
-
6. Recent advances in the field of non-coding RNAs in cancer
- Prof. George Calin
- Dr. Maitri Shah
-
7. How tumor-microenvironment interactions drive or inhibit metastasis
- Prof. Isaac P. Witz
-
8. A novel cancer therapy to stimulate oncogenic ERK signalling
- Prof. Reiko Sugiura
-
9. MRD-driven multiple myeloma treatment: next step forward
- Prof. Ola Landgren
-
11. Germinal centre lymphomas: advances in diagnostic and therapeutic intervention
- Dr. Koorosh Korfi
- Prof. Jude Fitzgibbon
-
12. Immunotherapy in lung cancer
- Dr. Mark M. Awad
-
13. Preservation of fertility in cancer patients: the impact of chemotherapy
- Prof. Kutluk H. Oktay
-
15. Solution proposed to a 2000 year old problem in oncology
- Dr. Michael Retsky
- Clinical Practice
-
16. Stillbirth: diagnosis, investigation and aftercare
- Prof. Alexander E. P. Heazell
-
17. Analyzing the medical relevance of skin care trends
- Prof. Zoe Draelos
-
18. Genetic counseling: preconception, prenatal, perinatal
- Prof. Aubrey Milunsky
-
19. The past, present & future of ANA testing: history and challenges of ANA
- Prof. Marvin J. Fritzler
-
20. The past, present & future of ANA testing: changing bandwidth and future of ANA
- Prof. Marvin J. Fritzler
-
22. Mitochondrial diseases: an update
- Dr. Ayesha Saleem
-
23. Hemophilia A
- Dr. Snejana Krassova
-
26. Recent advances in diagnosis and interventions in ophthalmology
- Dr. Rebecca Kaye
- Prof. Andrew Lotery
- Gastroenterology
-
27. Building implantable human liver tissue from pluripotent stem cells
- Prof. David C. Hay
-
28. Microbiome therapies to treat gastrointestinal diseases
- Dr. Patricia Bloom
-
29. Drug-induced liver injury: importance, epidemiology, and mechanisms of DILI
- Prof. James H. Lewis
-
30. Drug-induced liver injury: risk factors and drug development in DILI
- Prof. James H. Lewis
-
31. Drug-induced liver injury: HDS, diagnosing, treating and preventing DILI
- Prof. James H. Lewis
-
32. An update on the multiple faces of celiac disease
- Prof. Aaron Lerner
- Immunology
-
33. Harnessing the immune system for cancer therapy
- Dr. Raghav Sundar
-
34. Rac-enhanced CAR immunotherapy: RaceCAR
- Prof. Denise Montell
-
35. Enhancing innate anti-tumour immunity: lessons from virotherapy and STING agonism 1
- Prof. Kevin Harrington
-
36. Enhancing innate anti-tumour immunity: lessons from virotherapy and STING agonism 2
- Prof. Kevin Harrington
-
37. Drug allergy: new knowledge
- Prof. Mariana C. Castells
-
38. Biologics as a treatment strategy in food allergy
- Prof. Sayantani B. Sindher
-
39. B cells at the crossroads of autoimmune diseases
- Dr. Xiang Lin
-
40. Studying immune responses “one cell at a time”
- Dr. Mir-Farzin Mashreghi
-
41. Mathematical modeling in immunology
- Prof. Ruy M. Ribeiro
-
42. Therapeutic antibody development
- Prof. Dr. Katja Hanack
-
43. Understanding treatment coverage in mass drug administrations
- Dr. Margaret Baker
-
44. The thymus and T cell development: a primer
- Prof. Georg Holländer
- Infectious Diseases
-
46. The Global Virus Network: collaboration to address pandemic and regional threats
- Prof. Sten H. Vermund
-
47. New concepts in the management of CAP: a focus on severe illness - treatment and therapies
- Prof. Michael S. Niederman
-
48. New concepts in the management of CAP: a focus on severe illness - MRSA and MDR pathogens
- Prof. Michael S. Niederman
-
49. CRISPR-based suppression drives for vector control
- Prof. Andrea Crisanti
-
50. HIV cure: harnessing innate and adaptive strategies
- Prof. Luis Montaner
- Cardiovascular, Metabolism & Nutrition
-
51. Cow’s milk allergy: the future
- Dr. Carina Venter
-
52. Cow's milk allergy: management
- Dr. Carina Venter
-
53. Moving from GWAS hits to functional variants
- Prof. Steve Humphries
-
54. X-linked hypophosphataemia: genetics, diagnosis and management
- Prof. Thomas O. Carpenter
-
55. What is new in type 1 diabetes?
- Prof. Åke Lernmark
-
56. Current concepts for the management of patients with osteoporosis
- Dr. Michael Lewiecki
-
57. Antibodies to control or prevent type 1 diabetes
- Dr. Robert Hilbrands
-
58. Peptide YY (PYY) in obesity and diabetes
- Dr. Nigel Irwin
- Microbiology
-
59. Vaccines and the fight against antimicrobial resistance 1
- Dr. Annaliesa S. Anderson
-
60. Vaccines and the fight against antimicrobial resistance 2
- Dr. Annaliesa S. Anderson
-
61. Vaccines as a weapon against antibiotic resistance
- Dr. Pumtiwitt McCarthy
-
62. PathoLive: pathogen detection while sequencing
- Dr. Simon Tausch
-
64. Successes and failures with vaccines
- Prof. Stanley Plotkin
-
65. Immunology, the microbiome and future perspectives
- Prof. Sheena Cruickshank
-
66. Impact of the HPV vaccine programme – a changing landscape
- Dr. Kevin Pollock
- Neurology and Neuroscience
-
68. Huxley’s science fiction: ion channels in pain, pain resilience, and beyond
- Prof. Stephen Waxman
-
69. Advances in the diagnosis and treatment of tardive dyskinesia
- Prof. Emeritus Stanley N. Caroff
-
70. Cellular therapies for neurological Injuries: bioreactors, potency, and coagulation
- Prof. Charles S. Cox, Jr.
-
71. Cardiovascular involvement in Parkinson’s disease
- Dr. David S. Goldstein
-
72. Molecular brain imaging (PET) in diseases with dementia
- Prof. Karl Herholz
-
73. Current thinking in pain medicine and some thoughts on back pain
- Dr. Nick Hacking
-
74. Bioelectronic medicine: immunomodulation by vagus nerve stimulation
- Prof. Paul Peter Tak
-
75. Developments & future directions in the management of chronic pain
- Prof. Simon Haroutounian
-
76. Deep Brain Stimulation (DBS) neuromodulation for Schizophrenia
- Prof. Judith Gault
-
77. Parkinson’s at 200 years: an update on Parkinson’s research in 2017
- Prof. Patrick A. Lewis
-
78. Alzheimer's disease: where are we up to?
- Prof. John Hardy
- Pharmaceutical Sciences
-
79. Pharmacokinetics, -dynamics and dosing considerations in children
- Prof. Dr. Karel Allegaert
-
80. Why in vitro permeation test – and not in vivo?
- Prof. Howard Maibach
-
81. The future of plasma-derived medicinal products (PDMP)
- Dr. Daniele Focosi
-
82. RNA therapeutics: clinical applications and methods of delivery
- Prof. John P. Cooke
-
83. Recent advances in the development of gene delivery technologies
- Dr. Takis Athanasopoulos
-
84. Preclinical translation of mesenchymal stem cell therapies
- Dr. Peter Childs
-
85. Modulating gene expression to treat diseases
- Dr. Navneet Matharu
-
86. Accelerating drug discovery with machine learning and AI
- Dr. Olexandr Isayev
-
87. AI and big data in drug discovery
- Mr. Ed Addison
-
88. Emerging big data in medicinal chemistry: promiscuity analysis as an example
- Prof. Dr. Jürgen Bajorath
- Dr. Ye Hu
-
89. Binding kinetics in drug discovery
- Dr. Rumin Zhang
-
90. Modeling of antibody-drug conjugate pharmacokinetics
- Dr. Dhaval K. Shah
-
91. Antibody engineering: beginnings to bispecifics and beyond
- Dr. Ian Wilkinson
-
92. Current challenges in the design of antibody-drug conjugates
- Prof. L. Nathan Tumey
-
93. Inorganic nanostructured interfaces for therapeutic delivery
- Prof. Tejal Desai
-
94. Latest development in therapy-related autophagy research
- Dr. Vignir Helgason
- Respiratory Diseases
-
95. Respiratory syncytial virus vaccination
- Prof. Peter Openshaw
-
96. Advances in gene therapy for respiratory diseases 1
- Prof. John F. Engelhardt
-
97. Advances in gene therapy for respiratory diseases 2
- Prof. John F. Engelhardt
-
98. Asthma
- Prof. William Busse
- Dr. Amanda McIntyre
-
99. New drugs for asthma
- Prof. Peter Barnes
-
100. CompEx asthma: a novel composite exacerbation endpoint
- Dr. Carla A. Da Silva
-
101. Updates in chronic obstructive pulmonary disease (COPD)
- Dr. Omar S. Usmani
Printable Handouts
Navigable Slide Index
- Introduction
- Overview
- Inflammatory neuropathies
- Clinical spectrum
- Clinical presentation
- Spectra
- Acute inflammatory neuropathies
- Chronic inflammatory neuropathies
- Pattern in “typical” cases
- GBS versus CIDP
- Targets and mechanisms
- Potential mechanisms
- Potential effector mechanisms for nerve injury
- Methods to study or define pathological mechanisms
- Early evidence for neuropathy-associated anti-carbohydrate antibodies
- IgG antibodies to ganglioside in GBS
- Anti-ganglioside antibodies in the inflammatory neuropathies
- A true case of molecular mimicry?
- The node as a target for inflammatory neuropathy-associated antibodies
- Induced pluripotent SC derived sensory neurons
- Ganglioside antibody targeting nodal axolemma
- Calcium influx in sensory soma
- Calcium fluxes are a prelude to axonal degeneration
- Analysis of the electrophysiological effects of disialosyl antibodies and complement
- Reversible conduction failure vs. axonal degeneration
- GM1 & sulfatide antibodies may target glia directly
- Glial injury is followed by axolemmal nanoruptures, calcium influx, and secondary axonal degeneration
- Myelin proteins and T cells?
- The node of Ranvier
- Identification of specific antigens by immunoprecipitation
- Nodal/paranodal reactive antibodies in patients with inflammatory neuropathies
- Nodal/paranodal antibody syndromes: autoimmune nodopathies
- Nodal and paranodal antibody-associated neuropathies
- IgG4
- IgG4 does not activate complement
- Anti-contactin IgG4 antibodies have a (potentially) pathogenic “blocking” effect
- Anti-contactin IgG4 antibodies can disrupt nodal architecture
- Anti-neurofascin-155 IgG4 antibodies prevent paranodal complex formation in vivo
- Contrasting pathological importance of monovalent versus bivalent paranodal antibodies
- CNTN1 immune complexes drive nephropathy?
- CNTN1 positive immune complexes are found in glomeruli
- Anti-CNTNI IgG3 induces acute conduction block and motor deficits in a passive transfer rat model
- panNF antibodies activate complement and disrupt myelin, nodal, and paranodal structure
- Established and upcoming therapies
- Established therapies
- Plasma exchange
- IVIg
- Rituximab
- Treatments and their effects on neuropathies
- Autoimmune nodopathies: treatment implications
- Rituximab appears effective
- Other approaches
- Imlifidase: an approach to eliminate pathogenic IgG
- 15-HMedIdeS-09: imlifidase in GBS patients
- FcRN inhibition
- ARGX-113-1802/Adhere
- Complement inhibition with a C5 convertase blocking mAb precent MAC pore deposition
- Eculizumab maintains nerve terminal integrity and prevents functional impairment
- Complement inhibition in GBS
- ANX005
- Protection of axonal and nodal integrity via overexpression of calpastatin
- Summary
Topics Covered
- Inflammatory neuropathies
- Acute inflammatory neuropathies
- Chronic inflammatory neuropathies
- Guillain-Barré syndrome (GBS)
- Chronic inflammatory demyelinating polyradicuoloneuropathy (CIDP)
- Anti-ganglioside antibodies
- GM1 and sulfatide antibodies
- The node of Ranvier
- IgG4
- CNTN1 immune complexes
- Established and upcoming therapies
Links
Series:
- The Immune System - Key Concepts and Questions
- Periodic Reports: Advances in Clinical Interventions and Research Platforms
Categories:
Therapeutic Areas:
Talk Citation
Rinaldi, S. (2025, April 30). Immunology of the peripheral nervous system: the inflammatory neuropathies [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved May 9, 2025, from https://doi.org/10.69645/RLTQ4692.Export Citation (RIS)
Publication History
- Published on April 30, 2025
Financial Disclosures
- Dr. Rinaldi has received honoraria for lectures given at the request of Excemed, Fresenius, CSL Behring, UCB, argenx, the Beijing Association of Holistic and Integrated Medicine, and the Irish Institute of Clinical Neuroscience. He has been a paid consultant for argenx, Annexon, Dianthus, Takeda and Hansa Biopharma. He runs a not-for-profit diagnostic testing service for nodal/paranodal antibodies.
A selection of talks on Neuroscience
Transcript
Please wait while the transcript is being prepared...
0:00
Hello. I'm Simon Rinaldi.
I'm an Associate
Professor of Neurology.
The lecture today is going to
be about the immunology of
the peripheral
nervous system with
a particular focus on
inflammatory neuropathies.
0:13
In this lecture,
I'm going to cover
the clinical spectrum of the
inflammatory neuropathies,
targets, and mechanisms
of these disorders in
an immunological sense and
also talk about established
and upcoming therapies.
0:25
Inflammatory neuropathies can
broadly be defined as a range of
disorders characterized by
immune-mediated damage
to peripheral nerves.
Within this broad definition,
there is a wide range of
different possibilities,
different disorders, and
different immune-mediated
mechanisms.
0:47
We think about the
clinical presentation of
neuropathies in general and
inflammatory neuropathies
in particular,
these can be associated
with a range of symptoms.
We can think of positive sensory
features such as tingling,
burning, and pain; and
negative sensory features
such as numbness,
loss of sensation, loss of
dexterity, and imbalance.
There can also be
motor involvement
with loss of strength and
the cranial nerves and
autonomic nervous system
can also be involved.
This also translates
into the range of
signs that can be seen
on clinical examination.
This includes weakness, which
can be distal or proximal,
wasting, cranial nerve
dysfunction, fasciculations,
reduced muscle tone,
suppression of
the deep tendon reflexes, and
evidence of sensory loss,
sensory ataxia, and
autonomic dysfunction.
1:31
The inflammatory neuropathies
can be considered
and placed on a range
of different spectra.
For example, some are
acute reaching nodes
within four weeks;
whereas, others have ongoing
progression and nerve injury
beyond eight weeks in
what we consider chronic.
Similarly, they can
be monophasic with
a single node and
improvement or they
can be relapsing
remitting, or
chronic progressive.
They may be focal,
multifocal, or generalized.
They may be pure motor,
pure sensory, or
sensory motor and they may
affect proximal or
distal muscles, or both.
Furthermore, the pathology can
affect the myelin
sheath and cause
demyelinating
neuropathies or primarily
targeted at the axon and
cause axonal neuropathies.
Hide